- Home
- ITRM vs YI Comparison
ITRM vs YI Comparison
Compare ITRM & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- YI
- Stock Information
- Founded
- ITRM 2015
- YI 2010
- Country
- ITRM Ireland
- YI China
- Employees
- ITRM N/A
- YI N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- ITRM Health Care
- YI Consumer Staples
- Exchange
- ITRM Nasdaq
- YI Nasdaq
- Market Cap
- ITRM 40.0M
- YI 38.1M
- IPO Year
- ITRM 2018
- YI N/A
- Fundamental
- Price
- ITRM $0.62
- YI $4.43
- Analyst Decision
- ITRM Strong Buy
- YI
- Analyst Count
- ITRM 1
- YI 0
- Target Price
- ITRM $9.00
- YI N/A
- AVG Volume (30 Days)
- ITRM 985.2K
- YI 12.8K
- Earning Date
- ITRM 11-12-2025
- YI 11-26-2025
- Dividend Yield
- ITRM N/A
- YI N/A
- EPS Growth
- ITRM N/A
- YI N/A
- EPS
- ITRM N/A
- YI N/A
- Revenue
- ITRM N/A
- YI $1,979,883,442.00
- Revenue This Year
- ITRM N/A
- YI N/A
- Revenue Next Year
- ITRM $482.25
- YI N/A
- P/E Ratio
- ITRM N/A
- YI N/A
- Revenue Growth
- ITRM N/A
- YI N/A
- 52 Week Low
- ITRM $0.61
- YI $4.15
- 52 Week High
- ITRM $3.02
- YI $11.35
- Technical
- Relative Strength Index (RSI)
- ITRM 37.35
- YI 37.44
- Support Level
- ITRM $0.64
- YI $4.20
- Resistance Level
- ITRM $0.70
- YI $4.61
- Average True Range (ATR)
- ITRM 0.04
- YI 0.17
- MACD
- ITRM -0.01
- YI 0.05
- Stochastic Oscillator
- ITRM 2.20
- YI 24.14
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.